A healthcare company spun off from 3M in 2024, making medical-surgical supplies like wound care and infection prevention products, dental braces and aligners, and hospital software for managing billing and patient records, used by clinicians and health systems around the world. Its name blends "solving" and "momentum." A fun detail: the logo turns the letter S into an infinity symbol.
Organic sales rose 9.5% on advanced ERP orders, but operating income fell 15.8% as SG&A costs climbed to 42% of sales.
A pull-forward of customer orders ahead of a U.S. ERP deployment lifted organic sales. rose 2.2% to $2,209 million and expanded 3.8 points to 58.2%, but fell 15.4% to $181 million as accrued legal and separation costs pushed higher. The quarter's sales boost will reverse next period, leaving the underlying cost structure as the central question.
Key takeaways
of 9.5% was inflated by approximately $125 million in advanced customer orders placed ahead of a U.S. ERP system deployment, with a negative impact expected in Q3 2026 as normalizes.
Total fell 15.4% to $181 million, as rose to 42.0% of sales from 37.2% a year earlier, driven by accrued legal expenses and ongoing separation costs.
expanded 3.8 points to 58.2%, aided by a ~$120 million receivable recognized for IEEPA tariff refunds that reduced cost of product.
Section summaries
Management's Discussion and Analysis
Q2 2026 organic sales grew 9.5% aided by ~$125M in advanced ERP orders; total operating income fell 15.8% on higher corporate costs.
⌄
Total Q2 2026 rose 2.2% to $2,209M, with 9.5% offset by an 8.3% divestiture impact from the Purification and Filtration sale.
Approximately $125M in advanced customer orders ahead of a U.S. ERP deployment boosted Q2 sales, with a negative impact expected in Q3 2026 as normalizes.
MedSurg sales rose 12.7% on strength in I.V. site management and negative pressure wound therapy, while Dental Solutions grew 17.0% on restorative and orthodontic solutions.
was $227 million for the quarter, up 34.3% , but H1 cash from operations fell to $38 million from $198 million a year ago due to higher incentive compensation and 3M transition agreement exit payments.
The company announced plans to separate its Health Information Systems business as part of a portfolio optimization review, introducing execution and uncertainty risks.
What changed
as a percent of sales, flagged last quarter at 41.2%, rose further to 42.0% rather than tapering, as accrued legal expenses and separation costs offset the end of Purification and Filtration separation costs.
The PFAS indemnification from 3M ended after 2025; the company continues manufacturing relocation to exit 3M dependencies, with no new disclosure of disruption from the transition.
turned positive at $144 million after negative $273 million in Q1 2026, though H1 free cash flow remains negative at -$129 million.
fell to $4,573 million from $5,035 million at year-end 2025, continuing the deleveraging from Purification and Filtration sale proceeds.
What to watch
Track Q3 2026 organic sales and for the expected reversal of the ~$125 million in advanced ERP orders pulled into Q2.
Monitor as a percent of sales in Q3 2026 to see if the 42.0% level declines as accrued legal and separation costs taper.
Watch for any announcement or termination of the Health Information Systems strategic review and its impact on performance.
Follow quarterly against net on the remaining $4,573 million as H1 cash generation remains pressured.
MedSurg sales grew 12.7% (8.9% organic) driven by I.V. site management and negative pressure wound therapy, while Dental Solutions grew 17.0% (15.2% organic) on restorative and orthodontic solutions.
Total company margin declined to 8.2% from 9.9% as rose to 42.0% of sales due to accrued legal expenses and separation costs, while cost of product improved on IEEPA tariff refunds.
fell to $38M in H1 2026 from $198M a year ago on higher incentive compensation and 3M transition agreement exit payments; the company repurchased $288M in shares during Q2.
The company recognized a ~$120M receivable for IEEPA tariff refunds and announced plans to separate its Health Information Systems business as part of portfolio optimization.
Quantitative and Qualitative Disclosures About Market Risk
Foreign Currency Exchange Rate Risks: Solventum faces transactional exchange rate risk from transactions with customers in countries outside the United States and from intercompany transactions between affiliated entities. Foreign currency exchange rates and fluctuations in thos…
⌄
Foreign Currency Exchange Rate Risks:
Solventum faces transactional exchange rate risk from transactions with customers in countries outside the United States and from intercompany transactions between affiliated entities. Foreign currency exchange rates and fluctuations in those rates may cause fluctuations in cash flows related to foreign denominated transactions. The Company is also exposed to the translation of foreign currency earnings to the U.S. dollar.
Interest Rate Risk:
Solventum manages interest rate risk and expense using a mix of fixed and floating rate debt. In addition, the Company may enter into interest rate swaps that are designated and qualify as fair value hedges. The Company's interest rate sensitivity analysis includes the impact of interest rate changes on its floating-rate notes, interest rate swap agreements, and cash balances.
Commodity Price Risk:
Solventum manages commodity price risks through negotiated supply contracts and price protection agreements. The Company does not participate in material commodity hedging activity.
Discussion of legal matters is incorporated by reference from Part I, Item 1, Note 12, “Commitments and Contingencies,” of this document, and should be considered an integral part of Part II, Item 1, “Legal Proceedings.”
⌄
Discussion of legal matters is incorporated by reference from Part I, Item 1, Note 12, “Commitments and Contingencies,” of this document, and should be considered an integral part of Part II, Item 1, “Legal Proceedings.”